BCM
CLBT icon

Brooktree Capital Management’s Cellebrite CLBT Stock Holding History

Brooktree Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
25,783
+7,755
+43% +$102K 0.25% 36
2026
Q1 		$248K Buy
+18,028
New +$272K 0.2% 41

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Brooktree Capital Management's CLBT Position: Q2 2026 in Review

Brooktree Capital Management increased its Cellebrite (CLBT) stake by 43% in Q2 2026, buying an estimated $102K and bringing the position to 25,783 shares worth $376K. The position accounts for 0.25% of the portfolio, ranked #36.

Brooktree Capital Management first reported a position in CLBT in Q1 2026 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Brooktree Capital Management held 25,783 shares of Cellebrite worth $376K as of Q2 2026.
  • Brooktree Capital Management bought 7,755 Cellebrite shares in Q2 2026, an estimated $102K.
  • Cellebrite made up 0.25% of Brooktree Capital Management's portfolio in Q2 2026, its #36 holding.
  • Brooktree Capital Management first reported a position in Cellebrite in Q1 2026 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Brooktree Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.